Related references
Note: Only part of the references are listed.Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Biomarkers in bladder cancer: Translational and clinical implications
Liang Cheng et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma
Enken Drecoll et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2014)
Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome
Steven A. Schneider et al.
MODERN PATHOLOGY (2014)
Functionalized Polymeric Nanoparticles Loaded with Indocyanine Green as Theranostic Materials for Targeted Molecular Near Infrared Fluorescence Imaging and Photothermal Destruction of Ovarian Cancer Cells
Baharak Bahmani et al.
LASERS IN SURGERY AND MEDICINE (2014)
HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
Akihiko Yoshizawa et al.
LUNG CANCER (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Evaluación de la sobreexpresión de proteína HER2 en cáncer vesical no músculo invasivo con énfasis en el grado tumoral y en la recurrencia
A. Janane et al.
Actas Urologicas Espanolas (2013)
Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer
Ciara C. O'Sullivan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression
Paul Chih-Hsueh Chen et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis
Tobias Ettl et al.
HUMAN PATHOLOGY (2012)
HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder
Hans Olsson et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2012)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection
Hosny M. Behnsawy et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
Christian Bolenz et al.
BJU INTERNATIONAL (2010)
Bladder Cancer in 2010 How Far Have We Come?
Bruce L. Jacobs et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis
Y. H. Choi et al.
ANNALS OF ONCOLOGY (2009)
Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer
Kang Su Cho et al.
JOURNAL OF UROLOGY (2009)
Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
Surendra B. Kolla et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Histologic grading of noninvasive papillary urothelial neoplasms
Gregory T. MacLennan et al.
EUROPEAN UROLOGY (2007)
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Yuh-Shyan Tsai et al.
UROLOGIA INTERNATIONALIS (2007)
Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure
John P. Stein et al.
WORLD JOURNAL OF UROLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Expression of the epidermal growth factor receptor family in normal and malignant urothelium
R Rotterud et al.
BJU INTERNATIONAL (2005)
HER-2 and TOP2A coamplification in urinary bladder cancer
R Simon et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Microarray as a model for quantitative visualization chemistry
CFM Prinsen et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2003)
Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan
YS Tsai et al.
UROLOGIA INTERNATIONALIS (2003)
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
R Gandour-Edwards et al.
CANCER (2002)
Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma
BS Chang et al.
UROLOGY (2001)
Share Paper
